Kendall Capital Management Acquires Shares of 2,280 Medpace Holdings, Inc. $MEDP

Kendall Capital Management bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, Holdings Channel.com reports. The institutional investor bought 2,280 shares of the company’s stock, valued at approximately $1,207,000.

Several other institutional investors and hedge funds have also made changes to their positions in MEDP. Johnson Financial Group Inc. purchased a new stake in shares of Medpace in the second quarter valued at approximately $27,000. Geneos Wealth Management Inc. lifted its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares in the last quarter. Elyxium Wealth LLC purchased a new position in Medpace during the fourth quarter worth approximately $30,000. Allied Private Wealth LLC acquired a new position in Medpace during the second quarter worth $31,000. Finally, Kilter Group LLC acquired a new position in Medpace during the second quarter worth $31,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Medpace news, CEO August J. Troendle sold 27,174 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $618.79, for a total transaction of $16,814,999.46. Following the sale, the chief executive officer owned 561,195 shares in the company, valued at $347,261,854.05. This represents a 4.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Brian T. Carley sold 5,000 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total value of $3,043,150.00. Following the completion of the sale, the director directly owned 27,825 shares in the company, valued at $16,935,129.75. This represents a 15.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 122,261 shares of company stock worth $71,729,129 over the last three months. Company insiders own 20.50% of the company’s stock.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace’s latest earnings exceeded expectations, with quarterly EPS of $4.25 versus the $3.98 consensus estimate and revenue of $707.33 million versus $689.51 million expected. Revenue increased 17.2% year over year, while management maintained fiscal 2026 EPS guidance of $17.25 to $17.95. Why Is Medpace Up Since Its Last Earnings Report?
• Neutral Sentiment: Analyst sentiment remains mostly cautious. Three analysts rate Medpace a Buy and 10 rate it Hold, with a consensus price target of $584.18. Several firms raised their targets following the earnings report, but those targets remain below the stock’s recent trading level. Medpace Analyst Ratings and Price Targets
• Negative Sentiment: Several insiders sold shares on August 19–20. CEO August J. Troendle sold 42,783 shares for roughly $26.3 million, reducing his holdings by about 7% across the reported transactions. Directors Brian T. Carley and Fred B. Davenport Jr. sold 5,000 and 7,283 shares, respectively, reducing their positions by approximately 15% and 66%. While insider sales do not necessarily indicate deteriorating fundamentals, the cluster of transactions may weigh on investor sentiment. Medpace Insider Buying and Selling
• Negative Sentiment: Valuation is demanding, with Medpace trading at approximately 36 times earnings and a PEG ratio of 2.73. The stock is also near the upper end of its 52-week range, increasing sensitivity to profit-taking and any slowdown in growth.

Medpace Stock Up 1.3%

Medpace stock opened at $620.75 on Friday. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The firm has a market cap of $17.33 billion, a PE ratio of 36.39, a price-to-earnings-growth ratio of 2.77 and a beta of 1.15. The company’s 50 day moving average is $550.16 and its two-hundred day moving average is $492.71.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the previous year, the firm posted $3.10 earnings per share. The company’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on MEDP. Robert W. Baird raised their target price on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Mizuho lifted their price target on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Leerink Partners set a $620.00 target price on Medpace in a research note on Thursday, July 23rd. Finally, Truist Financial lifted their target price on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $584.18.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.